Anagrelide Hydrochloride；盐酸阿那格雷
货号：
IA4540
品牌：
Jinpan
暂无详情
产品简介
| 有效期 | 2年 |
| MDL | MFCD01720337 |
| EC | EINECS 680-360-9 |
| 别名 | BL-4162A；BMY-26538-01 |
| CAS | 58579-51-4 |
| 分子式 | C10H7Cl2N3O·HCl |
| 分子量 | 292.55 |
| 储存条件 | 2-8℃ |
| 纯度 | ≥98% |
| 外观（性状） | Off-white Solid |
| 单位 | 瓶 |
| 生物活性 | Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis. Anagrelide is an established platelet-reducing drug. [1-2]. |
| In Vitro | Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine [1]. |
| SMILES | ClC1=C(CN(C2)C3=NC2=O)C(N3)=CC=C1Cl.Cl |
| 靶点 | Phosphodiesterase (PDE) |
| 数据来源文献 | [1]. Pescatore, S.L. and C. Lindley, Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother, 2000. 1(3): p. 537-46. [2]. Petrides, P.E., Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 399-408. |
| 规格 | 10mg 25mg 50mg |
可选择性地影响血小板，用于原发性血小板增多症（血小板增多症）的相关研究。